Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-na??ve and plus-maze-experienced mice
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The notoriously inconsistent effects of cannabinoids on anxiety-like behaviour may be explained by recent research on CB1 receptor knockout (CB1-KO) mice suggesting that cannabinoids exert bidirectional effects via the CB1 receptor (anxiolysis) and a novel rimonabant-sensitive neuronal cannabinoid receptor (anxiogenesis). This hypothesis is supported by the anxiogenic-like profile of AM-251, an analogue of rimonabant that is a potent and selective CB1 receptor antagonist but which, unlike rimonabant, has no activity at the novel receptor. As we have previously shown that rimonabant reduces anxiety-like behaviour in test-experienced animals only, the current study assessed the effects of AM-251 (1.5-3.0 mg/kg) in male Swiss-Webster mice that were either plus-maze-naïve or had been exposed undrugged to the apparatus 24 h prior to testing. Results confirmed that prior maze experience per se significantly increases behavioural indices of anxiety without altering measures of general activity. In maze-naïve mice, the lower dose of AM-251 (1.5 mg/kg) significantly reduced % open-arm time and increased grooming while the higher dose (3.0 mg/kg) additionally reduced open-arm entries and total head-dipping, and increased closed-arm returns. These anxiogenic-like effects were observed in the absence of significant changes in general activity levels. Although AM-251 had a very similar profile in maze-experienced animals, significant drug effects on open-arm avoidance measures were precluded by experientially-induced changes in behavioural baselines (i.e. 'ceiling' effects). Nevertheless, AM-251 again significantly reduced total head-dipping and increased grooming (3.0 mg/kg) and, unlike effects in naïve animals, both doses markedly reduced time spent on the centre platform and increased time spent in the enclosed arms. Against a baseline of almost total open-arm avoidance, the pattern of behavioural change in maze-experienced mice would also be consistent with an anxiogenic-like action of AM-251. Data are discussed in relation to previous findings with rimonabant, the putative existence of a novel non-CB1 neuronal cannabinoid receptor and, more generally, the behavioural pharmacology of plus-maze 'trial 2'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“CB1 receptors are densely expressed in areas long associated with the regulation of emotional behaviour, including the hippocampus and amygdala (Herkenham et al., 1991; Matsuda et al., 1993; Tsou et al., 1999; Katona et al., 2001), where their activation is typically associated with presynaptically…”
BackgroundThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 3×
“, 2004), there are reports of both a normal (Marsicano et al., 2002) and an anxiolytic-like (DeGroot and Nomikos, 2004) phenotype.”
BackgroundModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 2×
“, 2000), prevention of anandamide hydrolysis by fatty acid amide hydrolase (FAAH) inhibitors produces anxiolytic-like effects in adult and infant rats (Kathuria et al., 2003).”
BackgroundKatona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218 · cited 1×
“Intriguingly, in both brain areas, CB1 receptors are localized to axon terminals of GABAergic interneurons that target principal cells expressing a2-subunit-enriched GABAA receptors (Katona et al., 1999, 2001; Hajos et al., 2000; Nyiri et al., 2001).”
BackgroundA new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716 · cited 1×
“As a2-GABAA receptors have recently been implicated in the anti-anxiety effects of benzodiazepines (reviewed by Mohler et al., 2002), this circuitry offers one plausible mechanism whereby cannabinoid receptor ligands may influence fear and anxiety.”
BackgroundKatona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668 · cited 3×
“areas long associated with the regulation of emotional behaviour, including the hippocampus and amygdala (Herkenham et al., 1991; Matsuda et al., 1993; Tsou et al., 1999; Katona et al., 2001), where their activation is typically associated with presynaptically mediated inhibition of transmitter release (Schlicker and…”
BackgroundLocalization of cannabinoid receptor mRNA in rat brain
Matsuda, L. A., Bonner, T. I., & Lolait, S. J. (1993) · Journal of Comparative Neurology · doi:10.1002/cne.903270406 · Cited by 631 · cited 2×
“areas long associated with the regulation of emotional behaviour, including the hippocampus and amygdala (Herkenham et al., 1991; Matsuda et al., 1993; Tsou et al., 1999; Katona et al., 2001), where their activation is typically associated with presynaptically mediated inhibition of transmitter release (Schlicker and…”
BackgroundActivation of Corticotropin-Releasing Factor in the Limbic System During Cannabinoid Withdrawal
Rodrı́guez de Fonseca, F., Carrera, M. R. A., Navarro, M., Koob, G. F., & Weiss, F. (1997) · Science · doi:10.1126/science.276.5321.2050 · Cited by 499 · cited 1×
“…light–dark exploration, social interaction and defensive withdrawal paradigms), with both anxiogenic-like (Onaivi et al., 1990; Rodriguez de Fonseca et al., 1997; Chakrabarti et al., 1998; Sulcova et al., 1998; Akinshola et al., 1999; Arevalo et al., 2001; Valjent et al., 2002; Finn et…”
BackgroundThe effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354 · cited 10×
“Thus, while the most widely used CB1 receptor antagonist rimonabant (SR141716A) has been found to have anxiolytic-like and/ or stress-inhibiting activity (Akinshola et al., 1999; Haller et al., 2002; Rodgers et al., 2003; DeGroot and Nomikos, 2004; Finn et al., 2004a; Haller et al., 2004; Griebel et al., 2005), there…”
BackgroundResultInfluentialPatel, S., Roelke, C. T., Rademacher, D. J., & Hillard, C. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03916.x · Cited by 297 · cited 2×
“…2003; DeGroot and Nomikos, 2004; Finn et al., 2004a; Haller et al., 2004; Griebel et al., 2005), there are also reports of anxiogenic-like and/or stress-potentiating effects (McGregor et al., 1996; Rodriguez de Fonseca et al., 1996; Navarro et al., 1997; Arevalo et al., 2001; Patel et al., 2005).”
Background
Cited by
Bortolato, M., Mangieri, R. A., Fu, J., Kim, J. H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.001 · Cited by 347
Rubino, T., Vigano', D., Realini, N., Guidali, C., Braida, D., Capurro, V., Castiglioni, C., Cherubino, F., Romualdi, P., Candeletti, S., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301664 · Cited by 345
Role in Anxiety Behavior of the Endocannabinoid System in the Prefrontal Cortex
Rubino, T., Realini, N., Castiglioni, C., Guidali, C., Vigano, D., Marras, E., Petrosino, S., Perletti, G., Maccarrone, M., Di Marzo, V., et al. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhm161 · Cited by 283
Moreira, F. A., Kaiser, N., Monory, K., & Lutz, B. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.005 · Cited by 281
Moreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 272
Metadata
- Authors
- Rodgers, R. J., Evans, P. M., & Murphy, A.
- Venue
- Behavioural Pharmacology
- Published
- 2005-09
- Volume
- 16
- Issue
- 5-6
- Pages
- 405-413
- ISSN
- 0955-8810 (ISSN-L)
- OpenAlex
- W2031023109
- Cited by
- 97
- References
- 14
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-na??ve and plus-maze-experienced mice. https://app.cochat.ai/papers/10.1097/00008877-200509000-00013
- The paper
- Rodgers, R. J., Evans, P. M., & Murphy, A. (2005). Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-na??ve and plus-maze-experienced mice. Behavioural Pharmacology. https://doi.org/10.1097/00008877-200509000-00013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.